AAAlsu Ruzalevna Akhunova

Alsu Ruzalevna Akhunova

*This is an algorithmically generated author record based on publicly available information.

Alsu Ruzalevna Akhunova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimizing transient transfection conditions in mammalian cell production lines for expression of classical swine fever virus E2 antigen

    by A. G. Galeeva, Y. A. Kuznetsova, A. R. Akhunova, N. I. Khammadov, K. S. Khaertynov, R. S. Mukhammadiev, M. A. Efimova

    Introduction. Despite no cases of classical swine fever (CSF) have been recorded in the Russian Federation since 2021, gaining official recognition, as a disease-free zone, will require adoption of effective, safe vaccines compatible with the DIVA strategy. A range of expression systems is being evaluated as potential platforms for a recombinant subunit vaccine; synthesizing the E2 antigen in mammalian cells appears to be a particularly promising approach. Objective. Optimizing transient transfection conditions in mammalian cell production lines for expression of classical swine fever virus (CSFV) E2 antigen. Materials and methods. The nucleotide sequence encoding a 188-amino acid fragment of the E2 antigen was cloned into the pVAX1 vector. Transient transfection was performed using two common methods – calcium-phosphate and cationic (employing branched polyethylenimine, PEI) – on three established mammalian production cell lines: CHO-K1, PK-15, and BHK-21/13. Expression efficiency was controlled using immunofluorescence, quantitative reverse transcription polymerase chain reaction, and enzyme-linked immunosorbent assay. Results. It was determined that all the cell lines evaluated underwent transfection with an efficiency ranging from 60 to 90%. Cellular viability 24 hours post-transfection was at least 87%, with the lowest rates observed following calcium-phosphate transfection using an initial 12-hour incubation period. In all cases, transfection was accompanied by expression of specific messenger RNAs. The highest yield of the 17.3 kDa recombinant E2 protein was achieved in the CHO-K1 cell line (up to 47.4 mg/L), while the lowest yield was observed in the BHK-21/13 line (up to 24.1 mg/L). The specificity ratio in the antigen variant of the indirect enzyme-linked immunosorbent assay using specific antisera ranged from 5.1 to 6.2 units for all the expressed protein variants. Conclusion. All the cell lines presented in the study demonstrated satisfactory transfection efficiency. Combined with their properties – such as high proliferation rates and adaptation to serum-free media – this makes them suitable for stable expression. Both the calcium-phosphate and cationic methods provide high transfection efficiency, relatively low cytotoxicity, and good reproducibility. The combined use of these control methods is advisable during the design phase of expression systems. In a production setting, however, the primary metric of their functionality is the overall yield of the specific recombinant protein, as determined by antigen-specific enzyme-linked immunosorbent assay.

  • ENZYME IMMUNOASSAY TEST SYSTEM FOR INTEROPERATIVE CONTROL OF THE SPECIFICITY OF RECOMBINANT CAPSID PROTEIN OF PORCINE CIRCOVIRUS TYPE 2

    by Yuliya Aleksandrovna Kuznetsova, Alsu Ruzalevna Akhunova, Antonina Glebovna Galeeva, Kamil Saubanovich Khaertynov, Marina Anatolyevna Efimova

    Porcine circovirus infections, primarily caused by porcine circovirus type 2 (PCV2), are one of the most significant problems in global pig production. Vaccination is a key tool for control and prevention of porcine circovirus infections. Recombinant analogs of capsid protein (rCap) of porcine circovirus type 2 (PCV2) are key components of modern diagnostic test systems and subunit vaccines. The stability of its antigenic activity is a critical parameter determining the efficiency and reproducibility of the functional product. The aim of this study was to develop and test an enzyme-linked immunosorbent assay system for interoperational monitoring of the specific activity of rCap protein. To obtain recombinant analogues of the PCV-2 capsid protein, the previously constructed recombinant E. coli BL21(DE3)pLysS-ORF2 producer strain (for prokaryotic analogue) and the stably expressing Chinese hamster ovary cell line CHO-K1/PCV-ORF2 (for eukaryotic analogue) were used; protein purification was performed according to previously developed protocols. Chromatographically purified IgG isolated from a pool of sera from PCV-2-seropositive pigs was used for sensitization of the solid phase (polystyrene plates); the specific peroxidase conjugate was obtained by the periodate method. The study resulted in the production of a stable peroxidase conjugate with a labeling density of 1.5:1. The developed test system enabled semiquantitative analysis of recombinant raw materials, demonstrating good reproducibility (coefficient of variation<7%). The test system was found to be universal and capable of assessing the activity of rCap variants obtained in both prokaryotic and eukaryotic expression systems, accurately recognizing their antigenic determinants. Thus, the implementation of the semiquantitative ELISA method in the production cycle will standardize the process of in-process quality control of biomass obtained using recombinant DNA technologies and guarantee stable antigenic characteristics of vaccines and diagnostic products.

  • Isolation and purification of recombinant bovine adenovirus type 3 hexone

    by A. R. Akhunova, A. G. Galeeva, A. I. Yarullin, M. A. Efimova, D. N. Mingaleev, R. Kh. Ravilov

  • Open Access

    Identification of bovine viral diarrhea virus variants — contaminants of industrial cell lines

    by A. G. Galeeva, A. R. Akhunova, N. I. Khammadov, D. A. Sorokina, A. I. Yarullin, A. M. Khafizova, Rishat S. Mukhammadiev, I. G. Karimullina

    Relevance. Contamination with bovine BVDV virus remains a threat to the quality of biological products. The most common factor of contamination is fetal bovine serum, the main factor supporting growth when cultivating cell lines, the use of which makes the risk of spreading the bovine BVDV virus almost inevitable.The aim of the study was to identify variants of bovine viral diarrhea virus, which are contaminants of production cell lines.Methods. The cell lines MDBK, BHK-21/13-02, PK-15, Vero and the production strains of the bovine HD virus NADL, VK-1 were used To amplify the target regions of the viral genome, oligonucleotide primers flanking the highly conserved untranslated region 5`UTR with a length of 289 bp were used. Comparative analysis of nucleotide sequences determined by sequencing was carried out using standard methods of molecular phylogenetics.Results. The fact of chronic infection with non-cytopathogenic bovine BVDV virus was confirmed in relation to the cell lines MDBK, BHK-21/13-02 and PK-15. Based on sequencing results, the contaminating virus variants were identified as representatives of subgenotype 1a. Phylogenetic analysis revealed their significant similarity between themselves and a number of strains isolated from persistently infected llamas, alpacas and roe deer with an identity of 96.8–99.2%. The presented data demonstrate the need for ongoing such screenings, which will improve the quality of technological raw materials used for the production of biological products, as well as improve existing means of serological diagnosis of infections caused by representatives of the Pestivirus genus.


  • Open Access

    Expression of the labeled recombinant glycoprotein E2 of the classical swine fever virus in E. Coli

    by A. G. Galeeva, M. A. Efimova, K. V. Usoltsev, Sh. M. Nasyrov, N. I. Hammadov, A. R. Akhunova, R. F. Khairullin, G. M. Yarullina

    Currently, live attenuated vaccines are used in the Russian Federation for the specific prevention of classical swine fever (CSF), but this strategy contradicts the rules for importing animal products and carries the risks of recombination with field strains. These factors exacerbate the need for further development of candidate recombinant vaccines with similar efficacy and safety. The aim of the presented work was to construct a prokaryotic expression system of the marked glycoprotein E2 of the CSF virus and to evaluate its immunochemical properties. As a result of the conducted studies, a section of the primary amino acid sequence of glycoprotein E2 of a highly pathogenic Shimen strain (subgenotype 1.1) was identified using bioinformatic analysis and a hybrid polypeptide was designed, including a non-specific (marker) part from the modified V5 epitope and a fragment of the BSA sequence. By cloning a codon-optimized fragment into the pET-28a vector, the E. coli BL21(DE3) pLysS/pET-28a/E2-V5 producing strain was constructed. During the optimization of the cultivation conditions of the producer strain, it was found that the highest yield of the target protein is achieved within 5-6 hours after the induction of expression. The immunochemical properties of chromatographically purified recombinant rE2-V5 were determined: for example, it was shown that its activity in indirect enzyme immunoassay exceeds that of native E2. The data obtained indicate the effectiveness of the developed prokaryotic expression system, which consists in proper folding, good solubility and the ability of the target protein to form specific immunocomplexes. The presence of a marker fragment in the expressed hybrid polypeptide in the future will allow using the latter as the basis of a recombinant vaccine that meets the requirements of the DIVA strategy.


  • Open Access

    Construction of prokaryotic system for expression of porcine circovirus type 2 ORF-2 gene fragment

    by A. G. Galeeva, A. R. Akhunova, K. V. Usoltsev, N. I. Khammadov, M. A. Efimova

    Porcine circovirus-associated diseases (PCVDs) are among the most significant challenges for pig farming in developed countries. Porcine circovirus type 2 (PCV-2) is considered the main etiological agent of postweaning multisystemic wasting syndrome in piglets. Mass PCVD occurrence has been reported in most regions of the world, that results in serious economic consequences. Optimal PCVD prevention is known to be achieved through a set of veterinary and sanitary measures in combination with vaccination. High evolutionary virus variability facilitating new genotype and strain emergence requires development of new candidate recombinant vaccines against PCV-2 infection. The study was aimed at construction of prokaryotic system for PCV-2ORF-2gene fragment expression and its functionality assessment. A genetic insert constructed from the most immunogenic type-specific PCV-2 epitopes based on genotype 2a, 2b, 2d strain and isolate consensus sequence was cloned into the expression vector pET-22b(+) that was incorporated into theEscherichia colistrain Rosetta 2(DE3). The transformants were selected based on the marker gene of ampicillin resistance on a selective medium. Target gene expression was induced by adding of isopropyl-β-D-1-thiogalactopyranoside at different concentrations. As a result,Escherichia coliRosetta 2(DE3)/pET-22b-ORF-2 strain, a producer of capsid protein fragment (92–233 amino acid residues), was constructed. It was found that in the presence of 1 mM isopropyl-β-D-1-thiogalactopyranoside, the expression level of soluble truncated rCap was 35–40 mg/L 6 hours after induction. The expression product was tested for its specificity with indirect ELISA using whole-virion PCV-2-hyperimmunized porcine serum. It was shown that the positivity coefficient of producer strain cell lysates averaged to 4.34 (p< 0.005). The recombinant rCap protein is suitable for serological diagnosis and is also of interest as a vaccine component, which is the goal of our further studies.